相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 保存条件:
低温
- 保质期:
详见说明
- 库存:
99
- 供应商:
上海圻明生物
- 规格:
50次
人非小细胞肺癌EGFR基因PCR试剂盒上海圻明生物优势供应。更多产品资料欢迎免费咨询。
One of the many important uses of PCR technology is that it can be used to label DNA probes with high specific activity. PCR technology has high specificity, and can synthesize probe DNA fragments in quantities within 1~2h if [α-32P]dNTP or other markers are added to the substrate
dNTPs, the probe DNA can be well labeled during DNA synthesis, and the incorporation rate of the marker can be as high as 70%~80%. Therefore, PCR labeling technology is particularly suitable for large-scale detection and non-radiolabeling. The disadvantage of this method is that a specific pair of PCR primers is synthesized.
Labeling can also be achieved by using small fragments prepared from probe DNA as primers.
Solution preparation
1. Prepare a stock solution
Unless otherwise stated, all unused stock solutions should be divided into disposable aliquots and stored at -20 °C after preparation. Avoid repeated freeze-thaw cycles.
1.1* Acid Stock Solution (125X):
Add 20 μL DMSO to *ate (component B) to make a 125X* acid stock solution.
2. Prepare standard solutions
*Salt standard solution
Add 50 μL of 1 mM KH2PO4 (Component C) to 950 μL of deionized water or enzyme reaction buffer to give a 50 μM * saline standard solution (PS7). A 50 μM * saline standard solution (PS7) was taken and serially diluted 1:2 to obtain a serially diluted phosphate standard with deionized water or enzyme reaction buffer.
3. Prepare a working solution
Add 20 μL of 125X* stock solution to 2.5 mL of sterile H2O and mix well to make a working solution of *salt. Avoid potential Pi contamination. Note: Avoid direct exposure of *salts (component B) to light. Due to the high sensitivity of this assay to Pi, it is extremely important to use Pi-free labware and reagents.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验筛查,如c-MET、ROS1的筛查,随着更多临床试验的验证,也在逐步应用于肺癌靶向治疗。一种新的肺癌预后模式。对于早期肺癌患者,预后较差,多由转移性病灶引起的复发。加利福尼亚大学旧金山分校UCSF通过研究361例Ⅰ-Ⅳ期非鳞癌非小细胞肺癌FFPE样本,检测14个癌基因及内参基因表达水平,制定预后算法。通过北加州与中国两组独立、双盲临床研究验证,表明该方法可以筛选早期NSCLC中“高风险”患者,完善Ⅰ期和Ⅱ期NSCLC患者的风险分层方法,帮助早期非鳞状NSCLC患者制定更有依据的诊疗策略,是一种基于基因
1 材料 1.1 组织来源 选取1998年1月-2000年6月外科手术切除的肺癌FPE标本40例[6],其中小细胞肺癌10例,非小细胞肺癌30例(腺癌15例,鳞癌15例),肺癌组织手术切除后常规经10%中性甲醛固定、石蜡包埋存档。5例手术切除后新鲜冰冻肺腺癌组织作为对照。所有组织前期均经免疫组织化 学染色证实无PML蛋白表达[6],见图1。入选病例均无术前放疗或化疗。 1.2 试剂和引物 R NA提取
率在30%以下)的晚期肿瘤有:小细胞肺癌、非小细胞肺癌、大肠癌、胃癌、卵巢癌、头颈部癌等;有一定疗效,但尚未证明能延长生存期的有:肾癌、黑色素瘤、前列腺癌、子宫内膜癌等。 肿瘤内科治疗的水平 1.可根治的肿瘤(治愈率>30%) 3.姑息疗效 滋养细胞肿瘤 肾癌 睾丸生殖细胞肿瘤 黑色素瘤 Hodgkin病
技术资料暂无技术资料 索取技术资料





